What is NRSN's current stock price?

NRSN (NeuroSense Therapeutics Ltd.) is currently trading at $0.82 with a market cap of $20.2M.

What sector is NeuroSense Therapeutics Ltd. in?

NeuroSense Therapeutics Ltd. (NRSN) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

NRSN NeuroSense Therapeutics Ltd.

Healthcare

$0.82+6.08%ClosedMarket Cap: $20.2M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

-13.35

P/S

0.00

EV/EBITDA

-3.14

DCF Value

$-0.03

FCF Yield

-0.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

173600.0%

ROA

-633.3%

ROIC

465.0%

Financials

View All

Period	Revenue	Net Income	EPS
FY null	$0.00	$-11.1M	$—
Q2 null	$0.00	$-2.4M	$—
Q1 null	$0.00	$-2.4M	$—
Q4 null	$0.00	$-1.8M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell

D. Boral CapitalBuy

2026-04-08

D. Boral CapitalBuy

2025-12-22

D. Boral CapitalBuy

2025-08-15

D. Boral CapitalBuy

2025-07-10

Trading Activity

Insider Trades

View All

Eisenberg Orofficer: Chief Financial Officer

SellWed Apr 01

Eisenberg Orofficer: Chief Financial Officer

SellWed Apr 01

Eisenberg Orofficer: Chief Financial Officer

SellWed Apr 01

Eisenberg Orofficer: Chief Financial Officer

SellWed Apr 01

Mandil-Levin Revitaldirector

SellTue Mar 31

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.58

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Peers